---
title: "Astrazeneca has launched its global strategic research and development center in Beijing"
description: "AstraZeneca has officially launched its new global strategic research center in Beijing. This research center is AstraZeneca's sixth globally and its second strategic research center in China, and it "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262725487.md"
published_at: "2025-10-25T09:47:52.000Z"
---

# Astrazeneca has launched its global strategic research and development center in Beijing

> AstraZeneca has officially launched its new global strategic research center in Beijing. This research center is AstraZeneca's sixth globally and its second strategic research center in China, and it is also a core project of AstraZeneca's $2.5 billion investment plan in China. It is reported that the Global R&D Beijing Strategic Center has an artificial intelligence and data science center, aimed at accelerating the translation of early drug research results into clinical development

According to Astrazeneca, it has officially launched a new global strategic research and development center in Beijing. This research center is Astrazeneca's sixth globally and its second strategic research and development center in China, and it is also a core project of Astrazeneca's $2.5 billion investment plan in China. It is reported that the Global R&D Beijing Strategic Center has an artificial intelligence and data science center, aiming to accelerate the translation of early drug research results into clinical development

### Related Stocks

- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Deutsche Bank  Keeps Their Sell Rating on AstraZeneca (AZN) | Deutsche Bank analyst Emmanuel Papadakis has maintained a Sell rating on AstraZeneca (AZN) with a price target of £115.0 | [Link](https://longbridge.com/en/news/276058097.md) |
| SLE and LN market expected to reach $5.9bn across 7MM by 2034 | A significant growth in the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major ma | [Link](https://longbridge.com/en/news/276212995.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/en/news/276017486.md) |
| TE Connectivity Poised to Gain From AI, Automotive Growth, Oppenheimer Says | TE Connectivity Poised to Gain From AI, Automotive Growth, Oppenheimer Says | [Link](https://longbridge.com/en/news/275928986.md) |
| 11:23 ETAI in Biotechnology Market Size to Reach USD 1,971 Million by 2031 \| Valuates Reports | The global AI in Biotechnology market is projected to grow from USD 1,033 million in 2024 to USD 1,971 million by 2031,  | [Link](https://longbridge.com/en/news/276147064.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.